Abbott Laboratories is trading at a slight premium, which suggests that the stock might be overvalued in the short term. The company's consistent dividend increases are a positive sign, but the inconsistency in revenue and return on invested capital may concern investors. Therefore, a neutral short-term impact is expected as investors might wait for a better entry point.